Grifols (NASDAQ:GRFS) Cut to “Sell” at BidaskClub

BidaskClub lowered shares of Grifols (NASDAQ:GRFS) from a hold rating to a sell rating in a report issued on Wednesday morning, BidAskClub reports.

GRFS has been the subject of a number of other research reports. Citigroup upgraded Grifols from a sell rating to a neutral rating in a report on Thursday, October 1st. Morgan Stanley restated an overweight rating on shares of Grifols in a report on Wednesday, December 9th. Zacks Investment Research cut Grifols from a buy rating to a hold rating in a report on Wednesday, November 4th. Finally, Berenberg Bank restated a buy rating on shares of Grifols in a report on Friday, October 30th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $20.00.

Grifols stock opened at $18.44 on Wednesday. Grifols has a 52 week low of $13.40 and a 52 week high of $25.73. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.33 and a current ratio of 2.93. The stock has a market capitalization of $12.68 billion, a P/E ratio of 16.46, a PEG ratio of 1.44 and a beta of 0.61. The stock has a 50-day simple moving average of $18.81 and a 200 day simple moving average of $18.14.

Grifols (NASDAQ:GRFS) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. Grifols had a return on equity of 10.65% and a net margin of 12.79%. The business had revenue of $1.52 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Research analysts forecast that Grifols will post 1.32 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GRFS. RMR Wealth Builders acquired a new stake in shares of Grifols in the second quarter valued at approximately $35,000. Signaturefd LLC raised its position in Grifols by 102.8% during the third quarter. Signaturefd LLC now owns 2,995 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 1,518 shares in the last quarter. Canton Hathaway LLC acquired a new position in Grifols during the third quarter valued at approximately $68,000. PNC Financial Services Group Inc. raised its position in Grifols by 70.8% during the second quarter. PNC Financial Services Group Inc. now owns 6,916 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 2,867 shares in the last quarter. Finally, Harding Loevner LP raised its position in Grifols by 9,180.4% during the third quarter. Harding Loevner LP now owns 9,002 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 8,905 shares in the last quarter. Institutional investors own 15.10% of the company’s stock.

Grifols Company Profile

Grifols, SA develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

See Also: What is a closed-end mutual fund (CEF)?

Analyst Recommendations for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.